← Leaderboards
Victor Robert Defilippis
Oregon Health & Science University
$6,530,438
Attributed
$6,530,438
Total exposure
6
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.5M · FY2007–25$2M$1.5M$1M$500K$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,530,438 · 6
By mechanism
R01$5,983,120 · 2
R21$409,293 · 1
P51$138,025 · 3
Top collaborators
No co-investigators on record.
Most similar at Oregon Health & Science University
Same institution · by research overlap
- Jonah B. Sacha$34,199,132
- Paul Kievit$12,790,994
- Christoph Adrian Kahl$3,227,415
- David C. Johnson$20,134,941
- Charles T Roberts$5,489,068
Others in their field
Top investigators on “Proteins”
- David Heimbrook · Leidos Biomedical Research, Inc.$354,061,551
- Randall J Bateman · Washington University$187,292,085
- Paul S. Aisen · Cognition Therapeutics, Inc.$175,382,342
- Reisa A. Sperling · Banner Health$145,046,481
- Barton F Haynes · Duke University$136,029,850
- Joseph L Goldstein · University Of Texas Sw Med Ctr/Dallas$102,433,280
Research focus
ProteinsIn VitroIn VivoImmune ResponseImmunityMacaca MulattaMolecularMediatingMouse ModelEnzymesImmunotherapeutic AgentImmunologicsMicrobeAntigen-Presenting CellsInnate Immune ResponseCellsDinucleoside PhosphatesImmuneAdaptive Immune ResponseInfectionAntigensExhibitsCyclic GmpLigands
Grant awards (13)
A Self-Adjuvanting Virus Like Particle Vaccine Platform for Emerging Viruses$782,723
R01 · FY2025 · AI · contact PI
A Self-Adjuvanting Virus Like Particle Vaccine Platform for Emerging Viruses$747,542
R01 · FY2024 · AI · contact PI
Mechanistic Exploration of cGAS-STING-Mediated Vaccine Enhancement$773,026
R01 · FY2023 · AI · contact PI
A Self-Adjuvanting Virus Like Particle Vaccine Platform for Emerging Viruses$767,562
R01 · FY2023 · AI · contact PI
Mechanistic Exploration of cGAS-STING-Mediated Vaccine Enhancement$787,088
R01 · FY2022 · AI · contact PI
Anti-tumor efficacy of novel cGAS-STING pathway agonists$214,767
R21 · FY2022 · CA · contact PI
Mechanistic Exploration of cGAS-STING-Mediated Vaccine Enhancement$768,168
R01 · FY2021 · AI · contact PI
Anti-tumor efficacy of novel cGAS-STING pathway agonists$194,526
R21 · FY2021 · CA · contact PI
Mechanistic Exploration of cGAS-STING-Mediated Vaccine Enhancement$640,563
R01 · FY2020 · AI · contact PI
Mechanistic Exploration of cGAS-STING-Mediated Vaccine Enhancement$716,448
R01 · FY2019 · AI · contact PI
THE ROLE OF CYTOMEGALOVIRUS PHOSPHOPROTEIN 65 IN VIRUS REPLICATON IN VIVO$34,471
P51 · FY2009 · RR · contact PI
THE ROLE OF CYTOMEGALOVIRUS PHOSPHOPROTEIN 65 IN VIRUS REPLICATON IN VIVO$27,704
P51 · FY2008 · RR · contact PI
THE ROLE OF CYTOMEGALOVIRUS PHOSPHOPROTEIN 65 IN VIRUS REPLICATON IN VIVO$75,850
P51 · FY2007 · RR · contact PI